Clinical Trial News and Research

RSS

Bioniche updates on phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer

Bioniche Life Sciences Inc. has provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer. On March 31st, the Company announced that recruitment had been completed in its initial Phase III registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is refractory (unresponsive) to the current standard immunotherapy - Bacillus Calmette-Guérin (BCG).

25 May 2009

Zyflamend, herb-based therapeutic shows promise for high risk of prostate cancer

Results of a phase I clinical trial of a novel herb-based therapeutic called Zyflamend have demonstrated that the therapy is associated with minimal toxicity and no serious adverse events in men at high-risk for developing prostate cancer.

22 May 2009

Scientists shed new light on why pancreatic cancer drugs can fail

Cancer Research UK scientists led an international team of investigators who have discovered a new mechanism that may explain why pancreatic cancer patients are often resistant to a common chemotherapy treatment called gemcitabine, according to a study published in Science.

22 May 2009

Research looks at ways to reduce the over-prescribing of antibiotics

Improving communications skills and the use of a simple blood test could help cut the growing number of inappropriate prescriptions of antibiotics, a joint Cardiff University trial has discovered.

22 May 2009

Trial tests potential new angina treatment

As part of a multi-center clinical trial, UC San Diego Medical Center is evaluating the safety and effectiveness of a potential new way to treat angina - by injecting a protein that stimulates the growth of new oxygen-rich blood vessels directly into the heart. Angina is a debilitating form of chest pain caused by coronary artery disease that affects more than nine million Americans.

20 May 2009

NIH to develop therapeutics for rare and neglected diseases

The National Institutes of Health is launching the first integrated, drug development pipeline to produce new treatments for rare and neglected diseases. The $24 million program jumpstarts a trans-NIH initiative called the Therapeutics for Rare and Neglected Diseases program, or TRND.

20 May 2009

Sucampo Pharmaceuticals initiates phase 3 trial of Lubiprostone for chronic idiopathic constipation in Japan

Sucampo Pharmaceuticals, Inc. today announced that its subsidiary, Sucampo Pharma, Ltd., has initiated enrollment and completed the randomization of the first patient into the pivotal phase 3 efficacy trial of lubiprostone for chronic idiopathic constipation (CIC) in Japan.

20 May 2009

Recommendations by experts to WHO on influenza A (H1N1) vaccines

Current epidemiological information suggests that the influenza A (H1N1) virus transmissibility potential is at least comparable to that of seasonal influenza viruses, with ability to sustain community spread. There is therefore no reason to expect that ongoing spread of the virus will stop.

19 May 2009

Cancer Research UK and Glaxosmithkline join forces to trial new anti-cancer drug

Cancer Research UK and Cancer Research Technology (CRT) today announced they will begin a phase I clinical trial of an anti-cancer drug from GlaxoSmithKline (GSK).

19 May 2009

Discovery of mutant genes in acute lymphoblastic leukemia

A research team has pinpointed a new class of gene mutations, which identify cases of childhood acute lymphoblastic leukemia (ALL) that have a high risk of relapse and death. The finding suggests specific drugs that could treat this high-risk leukemia subtype in children, particularly because such drugs are already in clinical trials for similar blood diseases in adults.

19 May 2009

Boston Scientific launches 3rd generation platinum chromium drug-eluting stent

Boston Scientific Corporation today announced the launch of the Platinum chromium Taxus Element Paclitaxel-Eluting Coronary Stent System in select markets worldwide. The Taxus Element Stent features a new Platinum chromium alloy engineered specifically for coronary stent applications and represents the Company's third-generation drug-eluting stent (DES) technology.

19 May 2009

Discovery in colon cancer prevention

A new study finds that individuals who have low expression of the "Celebrex gene," 15-PGDH, are actually resistant to Celebrex treatment when used to prevent colon cancer.

18 May 2009

FDA clears new treatment for facial wrinkles

Ellman International, Inc. announced today that the Food and Drug Administration (FDA) has granted clearance to Pelleve, a skin tightening system for the non-ablative treatment of mild to moderate facial wrinkles and rhytids for skin phototypes I-IV.

18 May 2009

Curcumin suppresses fat tissue growth in rodent models

Curcumin, the major polyphenol found in turmeric, appears to reduce weight gain in mice and suppress the growth of fat tissue in mice and cell models.

18 May 2009

New hope for warding off diabetes nerve loss

A common blood test for triglycerides - a well-known cardiovascular disease risk factor - may also for the first time allow doctors to predict which patients with diabetes are more likely to develop the serious, common complication of neuropathy.

18 May 2009

Saffron could stop blindness and cure eye disease

Italian scientists say they have found that saffron may hold the key to stopping vision loss as people age and in treating some eye diseases.

17 May 2009

Pirfenidone shows promise for idiopathic pulmonary fibrosis

A large, well-controlled, multi-national clinical trial program has demonstrated the effectiveness and safety of what may become the first FDA-approved medicine for idiopathic pulmonary fibrosis, or IPF.

17 May 2009

Early retroviral use best for AIDS patients with serious complications

HIV-positive patients who don't seek medical attention until they have a serious AIDS-related condition can reduce their risk of death or other complications by half if they get antiretroviral treatment early on, according to a new multicenter trial led by researchers at the Stanford University School of Medicine.

17 May 2009

Pazopanib shows promise for aggressive thyroid cancer

A medication that helps stop the growth of new blood vessels has produced dramatic benefits for some patients with aggressive thyroid cancer, research from Mayo Clinic indicates.

17 May 2009

Combining two chemotherapy drugs with Herceptin shows promise for metastatic HER2+ breast cancer

At the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), researchers from the Mayo Clinic campus in Florida report that using a combination of capecitabine, vinorelbine, and trastuzumab offers a treatment option that is at least as beneficial as other current options - and doesn't cause hair loss in patients.

17 May 2009